Trial Profile

An Open, Single-armed, Phase I Study to Evaluate the Safety and Efficacy Using Autologous TIL in Patients With Advanced Malignant Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous tumour infiltrating lymphocytes-Shanghai Juncell Therapeutics (Primary) ; Sintilimab
Indications Advanced breast cancer; Cervical cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Acronyms MIZAR-001
Sponsors Shanghai Gencells Therapeutics

Most Recent Events

27 Jan 2025 Planned End Date changed from 30 Apr 2025 to 30 Apr 2026.
27 Jan 2025 Planned primary completion date changed from 7 Nov 2024 to 7 Nov 2025.
16 Apr 2024 Planned primary completion date changed from 7 Nov 2023 to 7 Nov 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com